Summary

U.S. ATP Assays Market Size & Trends

The U.S. ATP assays market size was estimated at USD 1.10 billion in 2024 and is projected to register a CAGR of around 3.87% through 2033. The market is primarily driven by increasing demand for rapid, reliable testing methods across drug discovery, clinical diagnostics, environmental monitoring, and food safety applications. In drug development and clinical research, ATP assays play a key role in cell viability and cytotoxicity studies, while their use in environmental testing and food quality control supports contamination detection and hygiene verification. The growing need for high throughput, real time analysis across these sectors continues to support adoption of automated, luminescence based ATP platforms.

In addition, the rising number of samples being tested has led to the adoption of more advanced ATP assay systems that support faster and more efficient processing. Improvements in preparing, measuring, and managing samples have helped laboratories work more effectively and reduce delays. These changes benefit areas such as drug testing and contamination detection, where time and accuracy matter. In December 2024, Hygiena acquired Nexcor Food Safety Technologies Inc., strengthening its range of ATP and environmental monitoring products and supporting the growing demand for quick, reliable testing solutions.
Moreover, the U.S. ATP Assays market is witnessing a notable shift toward integrated and automated detection systems, particularly in pharmaceutical manufacturing and food quality control. These platforms are designed to streamline contamination monitoring and regulatory compliance by combining rapid testing capabilities with digital record-keeping and cloud-based analytics. The growing need for standardized, traceable, and high-throughput workflows drives adoption across various sectors. This shift aligns with broader trends emphasizing real-time data, operational efficiency, and adherence to evolving regulatory requirements, reinforcing the continued expansion of the U.S. ATP Assays market.

Furthermore, growing awareness of biosafety and quality assurance standards across healthcare, food production, and environmental sectors supports sustained investment in ATP assay technologies. Laboratories and production facilities are placing increased emphasis on minimizing contamination risks and meeting regulatory guidelines set by agencies such as the FDA and USDA. This has led to greater integration of ATP assays within quality control frameworks, particularly within environmental monitoring and routine screening workflows. With organizations prioritizing compliance and efficiency, the U.S. ATP Assays market is expected to benefit from stable, cross-sector demand for fast, accurate, and scalable testing solutions.

U.S. ATP Assays Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the U.S. ATP assays market on the test type,application, and end use:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Luminometric ATP Assays
• Enzymatic ATP Assays
• Bioluminescence Resonance Energy Transfer (BRET) ATP Assays
• Cell-based ATP Assays
• Others
• Application Outlook (Revenue, USD Million, 2021- 2033)
• Drug Discovery and Development
• Clinical Diagnostics
• Environmental Testing
• Food Safety and Quality Testing
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Hospital and Diagnostics Laboratories

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Application
1.2.3. End use
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in U.S.
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. Application outlook
2.2.3. End use outlook
2.3. Competitive Insights
Chapter 3. U.S. ATP Assays market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising emphasis on cell-based research in drug development
3.2.1.2. Increased adoption in food and beverage industry for hygiene monitoring
3.2.1.3. Expansion of biomanufacturing and bioprocess monitoring
3.2.2. Market Restraint Analysis
3.2.2.1. Limited specificity in complex biological samples
3.2.2.2. Availability of alternative assay techniques
3.3. U.S. ATP Assays market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. U.S. ATP Assays market: Type Estimates & Trend Analysis
4.1. Type Market Share, 2024 & 2033
4.2. Segment Dashboard
4.3. U.S. ATP Assays market by Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
4.4.1. Luminometric ATP Assays
4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.2. Enzymatic ATP Assays
4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.3. Bioluminescence Resonance Energy Transfer (BRET) ATP Assays
4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.4. Cell-based ATP Assays
4.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.5. Others
4.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. U.S. ATP Assays market: Application Estimates & Trend Analysis
5.1. Application Market Share, 2024 & 2033
5.2. Segment Dashboard
5.3. U.S. ATP Assays market by Application Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
5.4.1. Drug Discovery and Development
5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2. Clinical Diagnostics
5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.4.3. Environmental Testing
5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.4.4. Food Safety and Quality Testing
5.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.4.5. Others
5.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. U.S. ATP Assays market: End use Estimates & Trend Analysis
6.1. End use Market Share, 2024 & 2033
6.2. Segment Dashboard
6.3. U.S. ATP Assays market by End use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.4.1. Pharmaceutical and Biotechnology Companies
6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
6.4.2. Academic and Research Institutes
6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
6.4.3. Hospital and Diagnostics Laboratories
6.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2024
7.3.4. Thermo Fisher Scientific
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Promega Corporation
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. PerkinElmer Inc.
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Becton, Dickinson and Company (BD)
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Lonza Group Ltd.
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Danaher Corporation
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Abcam plc
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Quest Diagnostics Incorporated
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. Biomerieux SA
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
7.3.13. 3M Company
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Product benchmarking
7.3.13.4. Strategic initiatives